The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness: Main Results From the β-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS)
Open accessAbstract
Background —Statins reduce cardiovascular events and progression of carotid intima-media thickness (IMT). β-Blockers are also known to reduce cardiovascular events, but less is known about their effects on carotid IMT. Methods and Results —We conducted a randomized, double-blind, placebo-controlled, single-center trial to compare the effects of low-dose metoprolol CR/XL (25 mg once daily) and fluvastatin (40 mg once daily) on the progression of carotid IMT during 36 months of treatment in 793 subjects who had carotid plaque but no symptoms of carotid artery disease. Changes in mean IMT in the common carotid artery and maximal IMT in the bulb were the main outcome variables. Death and cardiovascular events were monitored. Progression of IMT max in the carotid bulb at both 18 and 36 months was reduced by metoprolol CR/XL (−0.058 mm/y; 95% CI, −0.094 to −0.023; P =0.004; and −0.023 mm/y; 95% CI, −0.044 to −0.003; P =0.014, respectively). Incidence of cardiovascular events tended to be lower in metoprolol CR/XL–treated patients (5 versus 13 patients, P =0.055). Rate of IMT mean progression in the common carotid at 36 months was reduced by fluvastatin (−0.009 mm/y; 95% CI, −0.015 to −0.003; P =0.002). Women in the fluvastatin group had increased frequency of transiently high liver enzymes. Conclusions —This is the first randomized trial to show that a β-blocker can reduce the rate of progression of carotid IMT in clinically healthy, symptom-free subjects with carotid plaque. This suggests that β-blockers may have a favorable effect on atherosclerosis development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Hjalmarson, Å., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., et al. (2000) · JAMA · doi:10.1001/jama.283.10.1295 · Cited by 1,399
Self-citation
Cited by
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Authors/Task Force Members:, Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehm236 · Cited by 2,384
Lakatta, E. G., & Levy, D. (2003) · Circulation · doi:10.1161/01.cir.0000048892.83521.58 · Cited by 2,244
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241
Metadata
- Authors
- Hedblad, B., Wikstrand, J., Janzon, L., Wedel, H., & Berglund, G.
- Venue
- Circulation
- Published
- 2001-04-03
- Volume
- 103
- Issue
- 13
- Pages
- 1721-1726
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2131334142
- Cited by
- 325
- References
- 2
- FWCI
- 13.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness: Main Results From the β-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). https://app.cochat.ai/papers/10.1161/01.cir.103.13.1721
- The paper
- Hedblad, B., Wikstrand, J., Janzon, L., Wedel, H., & Berglund, G. (2001). Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness: Main Results From the β-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation. https://doi.org/10.1161/01.cir.103.13.1721
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.